WilmerHale Advises Akebia Therapeutics in $50M Public Offering

WilmerHale Advises Akebia Therapeutics in $50M Public Offering

Client News

Related Solutions

Leveraging our sophisticated technical, market and legal experience to help clients effectively and efficiently manage complex transactions and get the deal done.
Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.

On March 19, 2025, Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, announced the pricing of its underwritten public offering of 25,000,000 shares of its common stock at a public offering price of $2.00 per share. The gross proceeds to Akebia from the offering, before deducting underwriting discounts, commissions and other offering expenses, are expected to be $50 million. In addition, Akebia has granted the underwriters a 30-day option to purchase up to 3,750,000 additional shares of its common stock at the public offering price, less underwriting discounts and commissions.

The WilmerHale team representing Akebia included Stuart Falber, Caroline Dotolo, Katharine Patterson, Rachael Joseph and Whitley Horning.

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.

I Accept Cancel